BioVie (BIVI) Stock Price, News & Analysis

Company Overview

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company developing therapies for neurological and liver diseases. The company focuses on treatments designed to address underlying disease mechanisms, including neuroinflammation, insulin resistance and fluid accumulation associated with advanced liver disease.

BioVie’s pipeline has included NE3107, an orally administered, blood-brain barrier-penetrant small molecule being investigated for neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease. The company has described NE3107 as having potential anti-inflammatory and insulin-sensitizing properties.

BioVie has also developed BIV201, a continuous-infusion formulation of terlipressin intended to treat refractory ascites, a serious complication of liver cirrhosis. The company conducts its research and clinical-development activities primarily through collaborations and clinical programs in the United States.

Key Stats

• Today's Range: $1.46 to $1.52
• 50-Day Range: $0.96 to $2.28
• 52-Week Range: $0.82 to $3.79
• Volume: 189,851 shs
• Average Volume: 336,269 shs
• Market Capitalization: $12.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

BioVie Stock Analysis - MarketRank™

BioVie scored higher than 9% of companies evaluated by MarketBeat, and ranked 847th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

BioVie has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

BioVie has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioVie is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioVie is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioVie has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.49% of the float of BioVie has been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 2.39, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently increased by 18.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioVie does not currently pay a dividend.

Dividend Growth

BioVie does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for BioVie this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for BIVI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of BioVie in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $49,118.00 in company stock, which represents 0.3876% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, BioVie insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,118.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.70% of the stock of BioVie is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

4.59% of the stock of BioVie is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/09/2026
• AGM 2026: 11/10/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIVI
• CIK: 1580149
• Web: bioviepharma.com
• Phone: (775) 888-3162
• Fax: N/A
• Employees: 13
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($3.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -126.02%
• Return on Assets: -108.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.59
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.36 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 8,680,000
• Free Float: 7,233,000
• Market Cap: $12.67 million
• Optionable: No Data
• Beta: 0.73